• CR Pharmaceutical Commercial, a non-wholly-owned subsidiary of China Resources Pharmaceutical Group, released unaudited consolidated results for January-September 2026.
• Net profit rose to RMB 1.75 billion from RMB 1.68 billion a year earlier.
• Revenue increased to RMB 169.46 billion from RMB 165.1 billion.
• Operating cash flow turned positive at RMB 327.97 million, versus an outflow of RMB 36.25 million a year earlier.
• Financing cash outflow widened to RMB 1.77 billion from RMB 510.73 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12390204), on October 30, 2026, and is solely responsible for the information contained therein.